{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:12:36Z","timestamp":1777126356930,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH08361"],"award-info":[{"award-number":["R25MH08361"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32MH126772"],"award-info":[{"award-number":["T32MH126772"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH121194"],"award-info":[{"award-number":["R01MH121194"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH134269"],"award-info":[{"award-number":["R01MH134269"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pre-exposure prophylaxis (PrEP) is a key biomedical tool for combatting HIV spread, but women account for only 5% of users. Between 2015 and 2019, men saw a 9% decrease in new HIV diagnoses, while rates among women remained constant. Using a difference-in-differences regression model and state level HIV surveillance data (utilizing sex assigned at birth) reported by AIDSVu from 2012 to 2021, we examined the impact of Medicaid expansions under the Affordable Care Act on PrEP outcomes. The study revealed that Medicaid expansions were associated with better PrEP outcomes overall, with increases of 18.9% in PrEP rate and 40.4% in PrEP-to-need ratio for every state that expanded Medicaid. Males experienced better outcomes with a 43% increase in PrEP-to-need ratio, while females saw a 15.6% increase that was not statistically significant. Medicaid expansion improves PrEP access for all, however more targeted strategies are needed to increase PrEP uptake among women vulnerable to HIV.<\/jats:p>","DOI":"10.1007\/s10461-025-04828-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:21:48Z","timestamp":1753708908000},"page":"3916-3930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["What Is the Effect of Medicaid Expansions on Preexposure Prophylaxis for HIV Prevention Use among Women?"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-7192","authenticated-orcid":false,"given":"Dion C.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia E.","family":"Rabionet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sannisha K.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"4828_CR1","unstructured":"Centers for Disease Control and Prevention. HIV in the Unites States and Dependent Areas. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/ataglance.html (accessed November 23, 2021)."},{"key":"4828_CR2","doi-asserted-by":"publisher","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States, JAMA, vol. 321, no. 9, pp. 844\u2013845, Mar 5 2019, https:\/\/doi.org\/10.1001\/jama.2019.1343","DOI":"10.1001\/jama.2019.1343"},{"key":"4828_CR3","doi-asserted-by":"publisher","unstructured":"Baeten JM et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women, N. Engl. J. Med., vol. 367, no. 5, pp. 399\u2013410, Aug 2 2012, https:\/\/doi.org\/10.1056\/NEJMoa1108524","DOI":"10.1056\/NEJMoa1108524"},{"key":"4828_CR4","doi-asserted-by":"publisher","unstructured":"Choopanya K et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, vol. 381, no. 9883, pp. 2083-90, Jun 15 2013, https:\/\/doi.org\/10.1016\/S0140-6736(13)61127-7","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"4828_CR5","doi-asserted-by":"publisher","unstructured":"Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. Dec 30 2010;363:2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205.","DOI":"10.1056\/NEJMoa1011205"},{"key":"4828_CR6","doi-asserted-by":"publisher","unstructured":"Thigpen MC et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana, N. Engl. J. Med., vol. 367, no. 5, pp. 423\u2013\u200934, Aug 2 2012, https:\/\/doi.org\/10.1056\/NEJMoa1110711","DOI":"10.1056\/NEJMoa1110711"},{"key":"4828_CR7","doi-asserted-by":"publisher","first-page":"699049","DOI":"10.3389\/fpubh.2021.699049","volume":"9","author":"BM Beech","year":"2021","unstructured":"Beech BM, Ford C, Thorpe RJ Jr., Bruce MA, Norris KC. Poverty, racism, and the public health crisis in America. Front Public Health. 2021;9:699049. https:\/\/doi.org\/10.3389\/fpubh.2021.699049.","journal-title":"Front Public Health"},{"key":"4828_CR8","unstructured":"K. Kaiser Family Foundation. The Impact of HIV on Black People in the United States. https:\/\/www.kff.org\/hivaids\/fact-sheet\/the-impact-of-hiv-on-black-people-in-the-united-states\/ (accessed April 8, 2025."},{"key":"4828_CR9","doi-asserted-by":"publisher","unstructured":"Frean M, Gruber J, Sommers BD. Premium subsidies, the mandate, and medicaid expansion: coverage effects of the affordable care act. J Health Econ, 53, pp. 72\u201386, 5\/\/ 2017, doi: https:\/\/doi.org\/10.1016\/j.jhealeco.2017.02.004","DOI":"10.1016\/j.jhealeco.2017.02.004"},{"key":"4828_CR10","unstructured":"U.S. Department of Health and Human Services. HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021\u20132025., 2021. Accessed: October 24, 2022. [Online]. Available: https:\/\/files.hiv.gov\/s3fs-public\/HIV-National-Strategic-Plan-2021-2025.pdf"},{"key":"4828_CR11","doi-asserted-by":"publisher","unstructured":"Allen DC, Rabionet SE, Popovici I, Zorrilla CD. Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention. J Pharm Health Serv Res. Sep 2022;13(3):168\u201371. https:\/\/doi.org\/10.1093\/jphsr\/rmac025.","DOI":"10.1093\/jphsr\/rmac025"},{"key":"4828_CR12","unstructured":"Centers for Disease Control and Prevention. Selected national HIV prevention and care outcomes. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/slidesets\/cdc-hiv-prevention-and-care-outcomes-2018.pdf (accessed February 18, 2022)."},{"key":"4828_CR13","unstructured":"Centers for Disease Control and Prevention. HIV and Women: HIV Diagnoses. https:\/\/www.cdc.gov\/hiv\/group\/gender\/women\/diagnoses.html (accessed December 25, 2021)."},{"key":"4828_CR14","doi-asserted-by":"publisher","unstructured":"Ya-lin AH, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity\u2014United States, 2014\u20132016, Morb. Mortal. Wkly. Rep. Surveill. Summ., vol. 67, no. 41, October 19 2018, doi: https:\/\/doi.org\/10.15585\/mmwr.mm6741a3","DOI":"10.15585\/mmwr.mm6741a3"},{"key":"4828_CR15","unstructured":"HIV.gov. Data & Trends: U.S Statistics. https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics (accessed November 9, 2024)."},{"issue":"5","key":"4828_CR16","doi-asserted-by":"publisher","first-page":"e0178737","DOI":"10.1371\/journal.pone.0178737","volume":"12","author":"RR Patel","year":"2017","unstructured":"Patel RR, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE. 2017;12(5):e0178737. https:\/\/doi.org\/10.1371\/journal.pone.0178737.","journal-title":"PLoS ONE"},{"key":"4828_CR17","doi-asserted-by":"publisher","unstructured":"Karletsos D, Stoecker C. Impact of medicaid expansion on PrEP utilization in the US: 2012\u20132018. AIDS Behav. Apr 2021;25(4):1103\u201311. https:\/\/doi.org\/10.1007\/s10461-020-03070-2.","DOI":"10.1007\/s10461-020-03070-2"},{"key":"4828_CR18","doi-asserted-by":"publisher","unstructured":"Siegler AJ, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, united States. Ann Epidemiol. Dec 2018;28(12):841\u20139. https:\/\/doi.org\/10.1016\/j.annepidem.2018.06.005.","DOI":"10.1016\/j.annepidem.2018.06.005"},{"key":"4828_CR19","doi-asserted-by":"publisher","unstructured":"Siegler AJ, the United States. Policy- and county-level associations with HIV pre-exposure prophylaxis use, 2018, Ann. Epidemiol., vol. 45, pp. 24\u201331 e3, May 2020. https:\/\/doi.org\/10.1016\/j.annepidem.2020.03.013","DOI":"10.1016\/j.annepidem.2020.03.013"},{"key":"4828_CR20","doi-asserted-by":"publisher","unstructured":"Harawa NT, Tan D, Leibowitz AA. Disparities in uptake of HIV Pre-Exposure prophylaxis among California medicaid enrollees. Health Aff (Millwood). Mar 2022;41(3):360\u20137. https:\/\/doi.org\/10.1377\/hlthaff.2021.01119.","DOI":"10.1377\/hlthaff.2021.01119"},{"key":"4828_CR21","doi-asserted-by":"publisher","unstructured":"Knight D, Saleem HT, Stockman JK, Willie TC. Experiences of black women in the united States along the PrEP care continuum: A scoping review. Aids Behav. Jul 2023;27(7):2298\u2013316. https:\/\/doi.org\/10.1007\/s10461-022-03960-7.","DOI":"10.1007\/s10461-022-03960-7"},{"key":"4828_CR22","doi-asserted-by":"publisher","unstructured":"Smit F, Masvawure TB. Barriers and facilitators to acceptability and uptake of Pre-Exposure prophylaxis (PrEP) among black women in the united states: a systematic review. J Racial Ethn Health Disparities. Oct 2024;11(5):2649\u201362. https:\/\/doi.org\/10.1007\/s40615-023-01729-9.","DOI":"10.1007\/s40615-023-01729-9"},{"key":"4828_CR23","unstructured":"Centers for Disease Control and Prevention. Paying for PrEP. https:\/\/www.cdc.gov\/hiv\/basics\/prep\/paying-for-prep\/index.html (accessed February 23, 2022)."},{"key":"4828_CR24","unstructured":"Kaiser Family Foundation. Medicaid and HIV. https:\/\/www.kff.org\/hivaids\/fact-sheet\/medicaid-and-hiv\/ (accessed February 24, 2022)."},{"key":"4828_CR25","unstructured":"AIDSVu. Tools and Resources. https:\/\/aidsvu.org\/resources\/#\/datasets (accessed January 28, 2022)."},{"key":"4828_CR26","doi-asserted-by":"publisher","unstructured":"Sullivan PS, et al. A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSVu public data resource. J Med Internet Res. Oct 23 2020;22(10):e23173. https:\/\/doi.org\/10.2196\/23173.","DOI":"10.2196\/23173"},{"key":"4828_CR27","unstructured":"K. Kaiser Family Foundation. Status of State Medicaid Expansion Decisions. https:\/\/www.kff.org\/status-of-state-medicaid-expansion-decisions\/ (accessed June 10, 2025."},{"issue":"12","key":"4828_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/M15-2234","volume":"164","author":"LR Wherry","year":"2016","unstructured":"Wherry LR, Miller S. Early coverage, access, utilization, and health effects associated with the affordable care act medicaid expansions: A quasi-experimental study. Ann Intern Med. 2016;164(12):795\u2013803.","journal-title":"Ann Intern Med"},{"issue":"10","key":"4828_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMsa1612890","volume":"376","author":"S Miller","year":"2017","unstructured":"Miller S, Wherry LR. Health and access to care during the first 2 years of the ACA medicaid expansions. N Engl J Med. 2017;376(10):947\u201356. https:\/\/doi.org\/10.1056\/NEJMsa1612890.","journal-title":"N Engl J Med"},{"issue":"4","key":"4828_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1475-6773.13311","volume":"55","author":"EO Blunt","year":"2020","unstructured":"Blunt EO, Maclean JC, Popovici I, Marcus SC. Public insurance expansions and mental health care availability. Health Serv Res. 2020;55(4):615\u201325.","journal-title":"Health Serv Res"},{"key":"4828_CR31","unstructured":"U.S. Census Bureau. County Business Patterns. https:\/\/www.census.gov\/programs-surveys\/cbp\/data\/tables.html (accessed February 15, 2022)."},{"key":"4828_CR32","unstructured":"Centers for Disease Control and Prevention. National Vital Statistics System, Mortality 1999\u20132020 on CDC WONDER Online Database. Data are from the Multiple Cause of Death Files, 1999\u20132020, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program.. [Online]. Available: http:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"4828_CR33","unstructured":"Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. [Online]. Available: https:\/\/gis.cdc.gov\/grasp\/nchhstpatlas\/tables.html"},{"key":"4828_CR34","doi-asserted-by":"publisher","unstructured":"Flood S, King M, Rodgers R, Ruggles S, Warren JW, Westberry M. Integrated Public Use Microdata Series, Current Population Survey: Version 9.0 [dataset]. https:\/\/doi.org\/10.18128\/D030.V9.0","DOI":"10.18128\/D030.V9.0"},{"key":"4828_CR35","doi-asserted-by":"publisher","unstructured":"Siegler AJ, et al. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the united states, 2018, (in eng). Ann Epidemiol. May 2020;45(e3):24\u201331. https:\/\/doi.org\/10.1016\/j.annepidem.2020.03.013.","DOI":"10.1016\/j.annepidem.2020.03.013"},{"key":"4828_CR36","doi-asserted-by":"publisher","unstructured":"Baugher AR, Finlayson T, Lewis R, Sionean C, Whiteman A, Wejnert C. Health care coverage and preexposure prophylaxis (PrEP) use among men who have sex with men living in 22 US cities with vs without medicaid expansion, 2017, (in eng). Am J Public Health. Apr 2021;111(4):743\u201351. https:\/\/doi.org\/10.2105\/ajph.2020.306035.","DOI":"10.2105\/ajph.2020.306035"},{"key":"4828_CR37","doi-asserted-by":"publisher","unstructured":"Chan PA, Seiler N, Chu CT. Leveraging medicaid to enhance preexposure prophylaxis implementation efforts and ending the HIV epidemic. Am J Public Health. Jan 2020;110(1):65\u20136. https:\/\/doi.org\/10.2105\/AJPH.2019.305416.","DOI":"10.2105\/AJPH.2019.305416"},{"key":"4828_CR38","doi-asserted-by":"publisher","unstructured":"Laufer FN, O\u2019Connell DA, Feldman I, Mps, Zucker HA. Vital signs: increased medicaid prescriptions for preexposure prophylaxis against HIV infection\u2013New york, 2012\u20132015. MMWR Morb Mortal Wkly Rep, 64, 46, pp. 1296\u2013\u2009301, Nov 27 2015, https:\/\/doi.org\/10.15585\/mmwr.mm6446a5","DOI":"10.15585\/mmwr.mm6446a5"},{"key":"4828_CR39","doi-asserted-by":"publisher","unstructured":"Bradley E, et al. Factors affecting Pre-Exposure prophylaxis implementation for women in the united states: A systematic review. J Womens Health (Larchmt). Sep 2019;28(9):1272\u201385. https:\/\/doi.org\/10.1089\/jwh.2018.7353.","DOI":"10.1089\/jwh.2018.7353"},{"key":"4828_CR40","doi-asserted-by":"publisher","unstructured":"Calabrese SK. Understanding, contextualizing, and addressing PrEP stigma to enhance PrEP implementation. Curr HIV\/AIDS Rep. Dec 2020;17(6):579\u201388. https:\/\/doi.org\/10.1007\/s11904-020-00533-y.","DOI":"10.1007\/s11904-020-00533-y"},{"key":"4828_CR41","doi-asserted-by":"publisher","unstructured":"Hynie M, Lydon JE. Women\u2019s perceptions of female contraceptive behavior: experimental evidence of the sexual double standard, Psychol. Women Q., vol. 19, no. 4, pp. 563\u2013\u200981, 1995, https:\/\/doi.org\/10.1111\/j.1471-6402.1995.tb00093.x","DOI":"10.1111\/j.1471-6402.1995.tb00093.x"},{"key":"4828_CR42","doi-asserted-by":"publisher","unstructured":"Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. Stigma, partners, providers and costs: potential barriers to PrEP uptake among US women. J AIDS Clin Res. Sep 2017;8(9). https:\/\/doi.org\/10.4172\/2155-6113.1000730.","DOI":"10.4172\/2155-6113.1000730"},{"key":"4828_CR43","doi-asserted-by":"crossref","unstructured":"Willie PR, Dale SK. Black women\u2019s sexual Well-being in the age of Pre-Exposure prophylaxis (PrEP): a systematic review of the literature. Curr Sex Health Rep, pp. 1\u201339, 2024.","DOI":"10.1007\/s11930-024-00388-z"},{"key":"4828_CR44","doi-asserted-by":"publisher","unstructured":"Nydegger LA, Dickson-Gomez J, Ko TK. Structural and syndemic barriers to PrEP adoption among black women at high risk for HIV: a qualitative exploration, (in eng). Cult Health Sex. May 2021;23(5):659\u201373. https:\/\/doi.org\/10.1080\/13691058.2020.1720297.","DOI":"10.1080\/13691058.2020.1720297"},{"key":"4828_CR45","unstructured":"Gelberg L, Andersen RM, Leake BD. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people, Health Serv. Res., vol. 34, no. 6, pp. 1273\u2013\u2009302, Feb 2000. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10654830"},{"key":"4828_CR46","doi-asserted-by":"publisher","unstructured":"Crooks N, et al. Barriers to PrEP uptake among black female adolescents and emerging adults. Prev Med Rep. Feb 2023;31:102062. https:\/\/doi.org\/10.1016\/j.pmedr.2022.102062.","DOI":"10.1016\/j.pmedr.2022.102062"},{"key":"4828_CR47","doi-asserted-by":"publisher","unstructured":"Devlin SA, et al. Adapting provider training and Pre-Exposure prophylaxis advertising to increase Pre-Exposure prophylaxis awareness and uptake among black cisgender women. AIDS Patient Care STDS. Dec 2023;37(12):574\u201382. https:\/\/doi.org\/10.1089\/apc.2023.0188.","DOI":"10.1089\/apc.2023.0188"},{"issue":"5","key":"4828_CR48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"key":"4828_CR49","doi-asserted-by":"publisher","unstructured":"Marrazzo JM et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med, 372, 6, pp. 509\u2013\u200918, Feb 5 2015, https:\/\/doi.org\/10.1056\/NEJMoa1402269","DOI":"10.1056\/NEJMoa1402269"},{"key":"4828_CR50","doi-asserted-by":"crossref","unstructured":"Cernasev A, Walker C, Armstrong D, Golden J. Changing the PrEP narrative: A call to action to increase PrEP uptake among women, Women, vol. 1, no. 2, pp. 120\u2013127, 2021.","DOI":"10.3390\/women1020011"},{"key":"4828_CR51","doi-asserted-by":"publisher","unstructured":"Sharpless L, et al. IPV, prep, and medical mistrust, (in eng). J Acquir Immune Defic Syndr. Jul 1 2022;90(3):283\u201390. https:\/\/doi.org\/10.1097\/qai.0000000000002956.","DOI":"10.1097\/qai.0000000000002956"},{"key":"4828_CR52","doi-asserted-by":"publisher","unstructured":"Brant AR, et al. Integrating HIV Pre-Exposure prophylaxis into family planning care: A RE-AIM framework evaluation, (in eng). AIDS Patient Care STDS. Jun 2020;34(6):259\u201366. https:\/\/doi.org\/10.1089\/apc.2020.0004.","DOI":"10.1089\/apc.2020.0004"},{"key":"4828_CR53","doi-asserted-by":"publisher","unstructured":"Zhang C, et al. HIV Pre-Exposure prophylaxis implementation cascade among health care professionals in the united states: implications from a systematic review and Meta-Analysis. AIDS Patient Care STDS. Dec 2019;33(12):507\u201327. https:\/\/doi.org\/10.1089\/apc.2019.0119.","DOI":"10.1089\/apc.2019.0119"},{"key":"4828_CR54","doi-asserted-by":"publisher","unstructured":"Garfinkel DB, Alexander KA, McDonald-Mosley R, Willie TC, Decker MR. Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients, (in eng). AIDS Care. Jun 2017;29(6):751\u20138. https:\/\/doi.org\/10.1080\/09540121.2016.1234679.","DOI":"10.1080\/09540121.2016.1234679"},{"key":"4828_CR55","doi-asserted-by":"publisher","unstructured":"Johnson A, et al. Awareness and intent to use Pre-exposure prophylaxis (PrEP) among African American women in a family planning clinic, (in eng). J Racial Ethn Health Disparities. Jun 2020;7(3):550\u20134. https:\/\/doi.org\/10.1007\/s40615-019-00683-9.","DOI":"10.1007\/s40615-019-00683-9"},{"key":"4828_CR56","doi-asserted-by":"publisher","unstructured":"Koren DE, Nichols JS, Simoncini GM. HIV Pre-Exposure Prophylaxis and Women: Survey of the Knowledge, Attitudes, and Beliefs in an Urban Obstetrics\/Gynecology Clinic, (in eng), AIDS Patient Care STDS, vol. 32, no. 12, pp. 490\u2013494, Dec 2018, https:\/\/doi.org\/10.1089\/apc.2018.0030","DOI":"10.1089\/apc.2018.0030"},{"key":"4828_CR57","doi-asserted-by":"publisher","unstructured":"Tekeste M, et al. Differences in medical mistrust between black and white women: implications for Patient-Provider communication about PrEP. Aids Behav. Jul 2019;23(7):1737\u201348. https:\/\/doi.org\/10.1007\/s10461-018-2283-2.","DOI":"10.1007\/s10461-018-2283-2"},{"key":"4828_CR58","unstructured":"Kanny D. Racial\/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men\u201423 urban areas, 2017. MMWR Morb Mortal Wkly Rep, 68, 2019."},{"key":"4828_CR59","doi-asserted-by":"publisher","unstructured":"Seiler N et al. Navigating the Intersection of PrEP and Medicaid, (in eng), J. Law. Med. Ethics, vol. 50, no. S1, pp. 60\u201363, 2022, https:\/\/doi.org\/10.1017\/jme.2022.38","DOI":"10.1017\/jme.2022.38"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04828-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04828-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04828-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T02:49:18Z","timestamp":1762138158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04828-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4828"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04828-2","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"12 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Unrelated to the information in this manuscript, Dr. Dale is a co-investigator on a Merck & Co. project examining biomedical HIV prevention preferences among at-risk women and has provided workgroup consulting for Gilead Sciences.\n                      All remaining authors have no relevant financial\n                      ,\n                      non-financial or competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The\n                      Nova Southeastern University\u2019s Institutional Review Board (IRB) conducted an exempt review and waived the need for an IRB approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}